CEL-SCI Corp (CVM) – Press Releases
-
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
-
CEL-SCI Corporation Issues Letter to Shareholders
-
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
-
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
-
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
-
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
-
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
-
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
-
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
-
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
-
CEL-SCI Issues Letter to Shareholders
-
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
-
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
-
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
-
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
-
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
-
CEL-SCI Announces Closing of Public Offering
-
CEL-SCI Announces Pricing of Public Offering
-
CEL-SCI Announces Proposed Public Offering of Common Stock
-
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
-
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
-
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
-
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
-
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
-
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
-
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
-
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
-
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
-
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
-
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
-
CEL-SCI Corporation Issues Letter to Shareholders
-
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
-
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
-
CEL-SCI Corporation Issues Letter to Shareholders
-
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
-
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
-
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
-
CEL-SCI Corporation to Present at LD Micro Invitational
-
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
-
CEL-SCI Announces Publication of ASCO 2022 Abstracts
-
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
-
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
-
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
-
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
-
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
-
CEL-SCI Corporation Issues Letter to Shareholders
-
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
Back to CVM Stock Lookup